09637

Dr. Runhong Xu, also known as Shirley, Ph.D., is Independent non-executive Director of Alebund Pharmaceuticals (Jiangsu) Limited from October 24, 2025. Dr. Xu has experience in the healthcare and pharmaceutical industry. From May 1993 to May 2024, she held multiple senior management positions at Baxter International Inc. (stock code: BAX.NYSE), including President of Greater China and global vice president, where she was primarily responsible for the strategic development and business operations in Greater China. From December 2024 to May 2026, she served as the Chief Growth Officer and Co-chairwoman of the Domestic Commercial Platform of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. where her main responsibilities include commercial strategy, product pipeline management and business operations and since May 2026, she has served as the Chief Executive Officer of the Fosun MedTech Division, fully responsible for its operation and management. Dr. Xu obtained a bachelor’s degree in medicine from Shanghai Jiao Tong University School of Medicine (previously known as Shanghai No. 2 Medical University in July 1991. She further obtained an executive master of business administration (EMBA) degree from China Europe International Business School in April 2003 and her doctorate degree in business administration (DBA) from City University of Hong Kong in February 2024.